Technology | Information Technology | June 20, 2019

Software provides dosimetry functionality for molecular imaging and molecular radiotherapy

DOSIsoft Receives FDA 510(k) Clearance for Planet Onco Dose Software

June 20, 2019 — DOSIsoft announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Planet Onco Dose software for its oncology and yttrium-90 (Y-90) microsphere SIRT 3-D dosimetry components.

Planet Onco Dose is a comprehensive software platform dedicated to medical diagnosis aid, therapy response assessment aid, contouring for radiotherapy and internal dosimetry computation, using molecular imaging modalities.

Planet Onco Dose is a modular software suite composed of two main elements:

  • Planet Onco: The oncology module with core system features, comprehensive reviewing of multimodal molecular image series (computed tomography, magnetic resonance imaging, positron emission tomography, single photon emission computed tomography), fusion and registration, automatic and semi-automatic contouring of regions of interest, tumor segmentation, quantification, tumoral activity monitoring and therapy response assessment; and

  • Planet Dose: The dosimetry module including 3-D personalized voxel-based internal dosimetry computation dedicated to molecular radiotherapy (MRT)

Planet Onco provides advanced tools to display, co-register (including deformable registration), compute standardized uptake value and import/export results (contours and quantification results) to/from treatment planning systems and picture archiving and communication system (PACS) devices for assessment, treatment planning and response of patients undergoing a course of oncology treatments.

DOSIsoft has transferred its external radiation therapy advanced software technology to nuclear medicine and molecular radiotherapy. CE marked since March 2016, Planet Onco Dose is the first fully integrated imaging and personalized 3-D dosimetry platform for radionuclide-based therapies, according to the company.

Planet Onco Dose is intended to assist the user in the diagnosis, quantification and verification of radiation doses received by tissues as a result of administering permanent Y90 microsphere implants, as well as in therapy response follow-up.

The software provides tools for post-treatment absorbed dose calculation and evaluation on PET and SPECT images. The following functions are available to allow dose calculations for patients after they have received a treatment using permanent Yttrium-90 microspheres:

  • Three-dimensional (3-D) liver-lung shunt assessment;

  • Voxel-based dosimetry based on 90Y-microspheres-PET (or SPECT Bremsstrahlung) series;

  • Dose computation models: Local Deposition Method and Voxel S Value Dose Kernel Convolution approach;

  • Analysis down to any liver sub region: healthy liver, lobes, tumors, toxicity regions;

  • Advanced and interactive dosimetry quantification (profile, dose-volume histograms, statistics, etc.);

  • Ability to scale to known activity; and

  • Compatible with PET images acquired with another radioisotope (correction of branching ratio and decay parameters).

For more information: www.dosisoft.com


Related Content

News | ASTRO

Oct. 5, 2026 — The American Society for Radiation Oncology (ASTRO) recognized the recipients of its 2026 Gold Medal ...

Time October 07, 2026
arrow
News | Radiopharmaceuticals and Tracers

Oct. 5, 2026 — GE HealthCare has announced a definitive agreement to acquire SOFIE Biosciences, a U.S.-based CMO for PET ...

Time October 06, 2026
arrow
News | Radiation Therapy

Oct. 1, 2026 — At ASTRO 2026 Elekta highlighted new data showing unprecedented long-term survival outcomes for patients ...

Time October 05, 2026
arrow
News | Stereotactic Body Radiation Therapy (SBRT)

Sept. 27, 2026 — Siemens Healthineers recently launched Accela, a radiotherapy solution engineered around NeoArc ...

Time October 01, 2026
arrow
News | ASTRO

Sept. 29, 2026 — The American Society for Radiation Oncology (ASTRO) has named Siemens Healthineers the inaugural ...

Time September 29, 2026
arrow
News | Proton Therapy

Sept. 28, 2026 — Penn Medicine and Ion Beam Applications (IBA) have formed Noventra Oncology Alliance, a new joint ...

Time September 28, 2026
arrow
News | ASTRO

Sept. 22, 2026 — Leading experts in radiation therapy from the Abramson Cancer Center (ACC) of the University of ...

Time September 24, 2026
arrow
News | Molecular Imaging

Sept. 22, 2026 — Blue Earth Diagnostics, a part of the Bracco Group, has announced new research examining how precision ...

Time September 23, 2026
arrow
News | PET Imaging

Sept. 22, 2026 — Researchers from the Keck School of Medicine of USC are developing a new “plug-and-play” platform that ...

Time September 23, 2026
arrow
News | ASTRO

Sept.16, 2026 — For appropriately selected patients with muscle-invasive bladder cancer, preserving the bladder can be a ...

Time September 17, 2026
arrow
Subscribe Now